ShockWave Medical Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ShockWave Medical in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ShockWave Medical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SWAV, but not buy additional shares or sell existing shares.
View analyst ratings for ShockWave Medical or view top-rated stocks.

Wall Street analysts have given ShockWave Medical a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ShockWave Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ShockWave Medical is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for ShockWave Medical.

ShockWave Medical will be holding an earnings conference call on Monday, August 9th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

ShockWave Medical, Inc. (NASDAQ:SWAV) posted its quarterly earnings data on Monday, May, 10th. The company reported ($0.68) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.26. The business earned $31.90 million during the quarter, compared to analyst estimates of $31.33 million. ShockWave Medical had a negative net margin of 83.47% and a negative trailing twelve-month return on equity of 30.92%. The business's quarterly revenue was up 109.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.59) EPS.
View ShockWave Medical's earnings history.

ShockWave Medical's stock was trading at $34.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SWAV shares have increased by 407.2% and is now trading at $174.68.
View which stocks have been most impacted by COVID-19.

ShockWave Medical issued an update on its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $195 million-205 million, compared to the consensus revenue estimate of $158.99 million.

7 Wall Street analysts have issued twelve-month price objectives for ShockWave Medical's shares. Their forecasts range from $152.00 to $208.00. On average, they expect ShockWave Medical's share price to reach $193.00 in the next twelve months. This suggests a possible upside of 10.5% from the stock's current price.
View analysts' price targets for ShockWave Medical or view top-rated stocks among Wall Street analysts.

8 employees have rated ShockWave Medical CEO Doug Godshall on Glassdoor.com. Doug Godshall has an approval rating of 89% among ShockWave Medical's employees.

Some companies that are related to ShockWave Medical include NovoCure (NVCR), Teleflex (TFX), Insulet (PODD), Abiomed (ABMD), Penumbra (PEN), Globus Medical (GMED), Hill-Rom (HRC), Tandem Diabetes Care (TNDM), Integra LifeSciences (IART), Nevro (NVRO), Inspire Medical Systems (INSP), Inari Medical (NARI), ICU Medical (ICUI), AtriCure (ATRC) and Merit Medical Systems (MMSI).
View all of SWAV's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ShockWave Medical investors own include NVIDIA (NVDA), The Walt Disney (DIS), Square (SQ), The Trade Desk (TTD), salesforce.com (CRM), Roku (ROKU), PayPal (PYPL), DexCom (DXCM), Alibaba Group (BABA) and Okta (OKTA).

(SWAV) raised $75 million in an initial public offering on Thursday, March 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

ShockWave Medical trades on the NASDAQ under the ticker symbol "SWAV."

ShockWave Medical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Fulton Bank N.A. (0.00%). Company insiders that own ShockWave Medical stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frank T Watkins, Frederic H Moll, Isaac Zacharias, Kurt F Gallo, Laura Francis and Sofinnova Capital Vii Fcpr.
View institutional ownership trends for ShockWave Medical.

SWAV stock was acquired by a variety of institutional investors in the last quarter, including Fulton Bank N.A..
View insider buying and selling activity for ShockWave Medical or or view top insider-buying stocks.

Shares of SWAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SWAV stock can currently be purchased for approximately $174.68.

ShockWave Medical has a market capitalization of $6.11 billion and generates $67.79 million in revenue each year. The company earns $-65,700,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis.

ShockWave Medical employs 449 workers across the globe.

The official website for ShockWave Medical is www.shockwavemedical.com.

ShockWave Medical is headquartered at 5403 Betsy Ross Drive, Santa Clara CA, 95054.

ShockWave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The company can be reached via phone at 510-279-4262 or via email at [email protected]